Prof. Shu Zhao 赵曙
Chief Physician, Professor
Department of Medical Oncology (II), Harbin Medical University Cancer Hospital, Harbin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Chemotherapy, immunotherapy, and targeted therapy for lymphoma, breast cancer, lung cancer, and gastrointestinal tumors. Specializes in treating relapsed or refractory lymphoma and high-dose chemotherapy.
Dr. Zhao holds a medical doctorate and serves as a professor and doctoral supervisor. In 2011, Dr. Zhao completed advanced studies at the Texas A&M Health Science Center in the US. Research focuses on lymphoma and breast cancer treatments. Dr. Zhao has published over 20 SCI-indexed articles and led multiple national and provincial research projects.
Professional roles
- Member, Lymphoma Professional Committee, China Anti-Cancer Association
- Vice Chair, Lymphoma Immunotherapy Professional Committee, Beijing Cancer Prevention and Treatment Society
- Member and Secretary, Lymphoma Branch, Heilongjiang Medical Association
- Standing Committee Member, Lymphoma Professional Committee, Heilongjiang Anti-Cancer Association
Name order: in Chinese the family name comes first (Zhao Shu). Papers usually list the name as Shu Zhao or Zhao S.
Selected publications
32 papers on PubMed matched by name and affiliation; 8 as first or senior author since 2016. Most recent first- or senior-author papers:
- Hematology, 2025 (senior author): Effect of metabolic syndrome on prognosis in patients with peripheral T-cell lymphoma. PubMed 41289509
- Ann Hematol, 2025 (senior author): Genomic mutation profile and metabolic alterations in diffuse large B-cell lymphoma with abdominal bulky mass. PubMed 40461894
- Clin Transl Oncol, 2024 (senior author): The effect of metabolic syndrome on prognosis of diffuse large B-cell lymphoma. PubMed 38554189
- Cancer Sci, 2024 (senior author): Pyroptotic macrophages promote proliferation and chemotherapy resistance of peripheral T-cell lymphoma via TLR4 signaling pathway. PubMed 38613253
- Pathol Res Pract, 2020 (senior author): TLR9 expression is associated with PD-L1 expression and indicates a poor prognosis in patients with peripheral T-cell lymphomas. PubMed 31879046
- Leuk Lymphoma, 2019 (senior author): The prognostic value of toll-like receptor5 and programmed cell death-ligand1 in patients with peripheral T-cell non-Hodgkin lymphoma. PubMed 31017033
- Cancer Manag Res, 2019 (first author): TLR4 expression correlated with PD-L1 expression indicates a poor prognosis in patients with peripheral T-cell lymphomas. PubMed 31191027
- Cancer Biol Med, 2018 (first author): The prognostic value of programmed cell death ligand 1 expression in non-Hodgkin lymphoma: a meta-analysis. PubMed 30197796
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion